China Biologic's Guizhou Taibang Subsidiary Donates Lifesaving Plasma Products for Injured in Train Disaster near Wenzhou

TAI'AN, China, July 26, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that through its Guizhou Taibang subsidiary, it has donated its life-saving plasma products (including 600 bottles 10-gram human albumin, 250 bottles 2.5-gram human immunoglobulin for intravenous injection, and 600 bottles 250IU human tetanus immunoglobulin) for the passengers and crew members who were injured in the train disaster near Wenzhou, Zhejiang Province of China. The donation was coordinated via the Wenzhou government officials and organizations in charge of the accident. The market value of the donation was close to RMB 600,000.

Mr. Chao Ming (Colin) Zhao, Chief Executive Officer of China Biologic, said, "Right after we heard of the tragedy, we immediately contacted the Ministry of Health and the Zhejiang Provincial Health Department to offer our products. We delivered our plasma shipment by express air for the injured victims of the terrible train crash that occurred near Wenzhou on July 23.

"These products are from our operations in Guizhou Province. We are fortunate to have a good supply of plasma products that are essential to the hospitals and surgical teams who are treating the injured. We thank the citizens of Guizhou Province, who have provided their valuable plasma to our company, for their substantial contribution in helping the injured and saving lives in the Wenzhou train accident.

"We extend our condolences to the families of the deceased and wish a prompt recovery to the injured. Our hearts, minds, and professional support are with you."

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China.

China Biologic is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website at www.chinabiologic.com for additional information.

Safe Harbor Statement

This news release may include forward-looking statements, including all assumptions, expectations, predictions, intentions, or beliefs about future events. Forward-looking statements can in some cases be identified by the use of forward-looking terminology such as "anticipates," "believes," "expects," "should," "will," or similar expressions. Factors that could cause actual results to differ materially from our forward-looking statements include our potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, and potential additional regulatory restrictions on our operations. For a description of additional risks and uncertainties that may cause actual results to differ from the forward-looking statements contained in this news release, please see our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), and our subsequent SEC filings. Copies of filings made with the SEC are available through the Company's website at www.chinabiologic.com and through SEC's website at www.sec.gov. Future business decisions are subject to change and the Company does not undertake to update the forward-looking statements contained in this news release except as required by law.